

03-26-02

Patent Application  
Attorney Docket No. PC10947A

GP/1624

#7  
RECEIVED

MAR 29 2002

TECH CENTER 16012900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: BEST, ET AL.

APPLICATION NO.: 09/918,152

Examiner: Not Yet Assigned

FILING DATE: JULY 30, 2001

Group Art Unit: 1624

TITLE: NOVEL PROCESS

Commissioner for Patents  
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: March 25, 2002  
Lorraine B. Ling  
Attorney for Applicant(s)  
Reg. No. 35,251Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212) 573-2030